Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.66 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 2/20 | 0.53 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.51 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.50 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396540 | 1.00 | NR4A2 (0.66) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| Bromide SCHEMBL1611919 | 0.98 | NR4A2 (0.63) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| Bromide SCHEMBL1611915 | 0.98 | NR4A2 (0.63) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL11519956 | 0.98 | NR4A2 (0.63) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| Bromide SCHEMBL1611912 | 0.94 | NR4A2 (0.59) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| Piperazine SCHEMBL2254509 | 0.89 | ADRB2 (0.61) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| SCHEMBL9357723 | 0.88 | NR4A2 (0.53) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| SCHEMBL1888577 | 0.83 | NR4A2 (0.66) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| SCHEMBL30051309 | 0.83 | NR4A2 (0.66) | NR4A2SOS2CYP1A2MAPTKMT2A | |
| SCHEMBL13747977 | 0.79 | NR4A2 (0.43) | NR4A2SOS2CYP1A2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731609-A1 | PRODUCTION PROCESS FOR HYDROXYCHLOROQUINE UNDER CONCENTRATED CONDITIONS | Tübitak (TR) | 2026-04-29 | — | — | EP | claimed |
| WO-2024261606-A1 | PRODUCTION PROCESS FOR HYDROXYCHLOROQUINE UNDER CONCENTRATED CONDITIONS | TÜBİTAK (TR) | 2024-12-26 | — | — | WO | claimed |
| US-12071410-B2 | High-yielding continuous flow synthesis of antimalarial drug hydroxychloroquine | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2024-08-27 | — | — | US | claimed |
| WO-2024147153-A1 | PEPTIDE-HISTIDINAL CONJUGATES AS AN ANTI-MALARIAL AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-07-11 | — | — | WO | claimed |
| CN-114989082-B | Efficient preparation method of hydroxychloroquine based on synergistic catalysis of I-valent copper compound and trisubstituted phosphine | 华东理工大学 | 2024-06-21 | — | — | CN | claimed |
| CN-113072491-B | Preparation method of hydroxychloroquine sulfate | 欣凯医药化工中间体（上海）有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-111423373-B | Preparation method of hydroxychloroquine sulfate | 瑞阳制药股份有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-117205211-A | Application of quinoline compound in preparation of fish parasitic protozoan resisting medicine | 西北农林科技大学深圳研究院 | 2023-12-12 | — | — | CN | claimed |
| CN-116715602-A | Fluorenyl oxalyl diamine compound, derivative and application thereof | 华东理工大学 | 2023-09-08 | — | — | CN | claimed |
| CN-112745263-B | Preparation method of hydroxychloroquine | 南京济群医药科技股份有限公司 | 2023-08-04 | — | — | CN | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| CN-1134424-A | Synthesis process of 2,3-disubstituted oxaziridine | YAN ZIMENG (CN) | 1996-10-30 | — | — | CN | claimed |
| EP-0000678-B1 | INTERMEDIATE FOR SYNTHESIS: GLYCERYLANTHRANILATE AND PROCESS FOR ITS PREPARATION | PIERRE FABRE S.A. (FR) | 1981-08-05 | — | — | EP | claimed |
| EP-0000679-B1 | PROCESS FOR THE PREPARATION OF GLAFENINE | PIERRE FABRE S.A. (FR) | 1981-06-24 | — | — | EP | claimed |
| EP-0000679-A1 | Process for the preparation of glafenine | PIERRE FABRE S.A. (FR) | 1979-02-07 | — | — | EP | claimed |
| EP-0000678-A1 | Intermediate for synthesis: glycerylanthranilate and process for its preparation | PIERRE FABRE S.A. (FR) | 1979-02-07 | — | — | EP | claimed |
| US-4119460-A | FUSED CARBOCYCLIC RING COMPOUNDS, POLYPHENYL COMPOUNDS NITROGEN-FREE POLYARYLATED COMPOUNDS | EASTMAN KODAK COMPANY (US) | 1978-10-10 | — | — | US | claimed |
| US-3988286-A | Heat curable poly(arylene sulfide) compositions | PHILLIPS PETROLEUM COMPANY (US) | 1976-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071410-B2 | High-yielding continuous flow synthesis of antimalarial drug hydroxychloroquine | POLQ, QTRT2, QTRT1 | NR4A2 4700/4885SOS2 2292/4885CYP1A2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.